TM Editors Note: This article discusses one or more penny stocks and/or microcaps. Such stocks are readily manipulated; do your own careful due diligence.

41 psychedelic drug stocks trade on the various North American stock exchanges and during this shortened week 15 went up in price,15 went down and 11 had no change for an overall sector change of +6.1%.

The 41 stocks consist of:

• 7 micro-cap stocks (Group #1) with an average market capitalization of $197M,
• 2 small-cap stocks (Group #2) with an average market capitalization of $1.16M,
• 32 nano-cap stocks (Group #3) with an average market capitalization of just $33M.

Below is the stock price performance for each Group for the week ending April 1st. :

Group #1

The 7 stocks in Group #1:

• have market capitalizations ranging from $104M to $315M and average $197M
• advanced 9.9% (+69.0% YTD) and
• ranged in price/share from $0.17/share to $5.08/share for an average of $2.07/share of which
• 3 trade for less than $1/share at $0.17/share, $0.39/share and $0.83/share as of yesterday, April 1st..
• and are constituents in the munKNEE Pure-Play Psychedelic Drug Stocks Index as their market capitalizations are more than $100M and less than $1B.

The performance of the Group #1 constituents were, in descending order (with YTD in brackets), as follows :

1. Seelos (SEEL): +18.7% (+221.5%) to $5.08/share
   • BTIG analyst Robert Hazlett put a $14 price target on SEEL stock
   •  analyst group B. Riley FBR added a buy rating and a price target of $15 per share for SEEL
2. Jaguar (JAGX): +7.6% (+144.4%) to $1.98/share
   • reported FY2020 ended December 31, 2020 results of a 63% increase in net sales and a 12% reduction in its net loss
3. Field Trip (FTRPF): +6.8% (+50.2%) to $4.88/share
   • closed a bought deal offering for $95 million upsized from the originally planned $50 million
4. Cybin (CLXPF): +2.7% (-24.7%) to $1.13/share
5. Revive (RVVTF): +2.6% (-20.4%) to $0.39/share
6. Numinus (LKYSF): +2.4% (+1.2%) to $0.85/share
7. Bionomics (BNOEF): -5.6% (+70.0%) to $0.17/share 

Group #2

The two stocks in Group #2:

• have market capitalizations of $920M and $1.4B
• advanced 8.4% (-20.4% YTD) as follows:
  • Mind Medicine (MMEDF): +14.9% (-6.2%) to $2.86/share
    • filed a base shelf prospectus in Canada and a corresponding Form F-10 registration in the U.S, which will enable the stock to trade on exchanges in these countries, dramatically expanding the company’s access to capital
    • reported FY2020 assets of $85.6 million ($80.1 million cash) and a net loss of $35.1 million but had no revenue to report
  • Compass Pathways (CMPS): +7.9% (-21.3%) to $37.50/share
    • gained coverage from Roth Capital, which gave the stock a price target of $88 as its CMPS stock forecast

The above two stocks are not eligible for inclusion in the munKNEE Pure-Play Psychedelic Drug Stocks Index as their market capitalizations are so large that their inclusion would skew the performance results of the index so are reported above separately.

Group #3

The 32 stocks in Group #3:

• have market capitalizations ranging from just $3M to $77M and average $33M
• declined 1.5% (-5.3% YTD) with 7 going up in price, 14 going down and 11 having no change in price
• of which 28 averaged $0.30/share (from $0.005/share to $0.52/share)
• and 4 averaged $0.88/share (from $0.70/share to $1.21/share)

The stocks in Group #3 are, in alphabetical order, as follows:

• Aion (CSE:AION), Algernon (AGNPF), Champignon (SHRMF), Codebase (BKLLF), Core One  (CLABF),  Ehave (EHVVF).  Entheon  (ENTBF), Graph Blockchain (REGRF), Havn (HAVLF), Hollister (HSTRF), Lobe Sciences (GTSIF),  M2BIO (WUHN), Mind Cure  (MCURF), Mindset (MSSTF), Minerco (MINE), Mydecine (MYCOF), Neonmind (NMDBF), Newscope-PharmaTher (CSE:PHRM), New Wave (TRMNF), Nova Mentis (NOVA), Novamind (NVMDF), NutritionalHigh (SPLIF),   Optimi (CSE: OPTI), PayBio (CSE: PSYB),   Psyched Wellness (PSYCF), Pysence (CSE: PSYG), Pure Extracts (PRXTF), Red Light (TRUFF), Silo Wellness (CSE: SILO), SILO Pharma (OTC: SILO) Tryp (TRYPF), and Thoughtful Brands (PEMTF)

The biggest movers were Aion (+29.6%) and Algernon (-24.0%).

The above 32 stocks are not eligible for inclusion in the munKNEE Pure-Play Psychedelic Drug Index as their market capitalizations are less than $100M.